H.C. Wainwright downgraded CytoSorbents to Neutral from Buy with a price target of $1, down from $5.50, after the company announced the STAR-T study did not meet its primary endpoint. The firm awaits the presentation of the final results, but to “remain conservative,” it removed all U.S.- related costs and revenues from its financial projections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CTSO:
- CytoSorbents says STAR-T trial did not meet primary effectiveness endpoint
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
- CytoSorbents announces closing of $10.3M registered direct offering
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
- CytoSorbents reports Q3 EPS (21c), consensus (12c)